pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
BRISTOL MYERS SQUIBB CO ($BMY) · news · pharmadog
← back to BRISTOL MYERS SQUIBB CO
News mentioning $BMY
153
stories
15d
No deal between AstraZeneca and BMS, senior source insists: Reuters
biospace
15d
Chaotic adcomms threaten to derail FDA’s bid to renew trust after Makary, Prasad
biospace
15d
STAT+: Pharmalittle: We’re reading about a Medicare pilot and orphan drugs, Pfizer cutbacks, and more
stat
15d
Merger talks between AstraZeneca, Bristol Myers are off — report
endpoints
15d
A COPD drug from China draws $115M in venture funding
biopharma dive
15d
Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms
biospace
16d
5 NextGen winners who went public this year (and which ones are hiring)
biospace
16d
4 potential biotech M&A targets, plus a pretty sure bet from J&J
biospace
16d
As portfolio erodes, BMS stands to gain a lot from rumored AstraZeneca merger
biospace
16d
Icon inks Anthropic partnership to deploy Claude into clinical trials
fiercebiotech
17d
Post-Hoc Live: Who wants an AstraZeneca-Bristol Myers megadeal?
endpoints
17d
Biopharma industry questions potential AstraZeneca, Bristol Myers merger
endpoints
17d
An AstraZeneca-Bristol Myers megamerger? Wall Street isn’t thrilled.
biopharma dive
17d
BioNTech taps Sobi executive Oelkers as its next CEO
biopharma dive
17d
Supernus and Indivior merge to create CNS mega-company with 11 approved drugs
biospace
17d
STAT+: Pharmalittle: We’re reading about AstraZeneca-Bristol merger talks, a revised 340B plan, and more
stat
17d
BioNTech picks Sobi CEO Oelkers to lead as founders plot new mRNA biotech
biospace
17d
‘Unlikely’ AstraZeneca-BMS mega-merger would be largest pharma deal ever
biospace
18d
BlossomHill eyes $112M IPO harvest to bankroll potential Tagrisso challenger
fiercebiotech
18d
After 5-month wait, BioNTech announces Sobi CEO will take on top job at mRNA company
fiercebiotech
18d
Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea
fiercebiotech
18d
AstraZeneca, Bristol Myers in talks about merger — report
endpoints
20d
Trump administration tries again to institute rebates in 340B
biopharma dive
20d
Moderna maintains 10% growth target despite Phase 3 norovirus miss
biospace
20d
Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOs
biopharma dive
20d
Ratio collects $70M for its radiopharmaceutical trials; Vogenx plans $67M IPO
endpoints
21d
Replimune overcomes ‘messy data’ to secure positive adcomm vote for melanoma therapy
biospace
21d
Replimune melanoma drug wins support of FDA panel
biopharma dive
21d
Replimune’s twice-rejected melanoma drug prevails in FDA adcomm
fiercebiotech
21d
Chutes & Ladders—Legend CEO departs without successor in place
fiercebiotech
← prev
page 2 of 6
next →
